OBJECTIVE: We compared the prevalence and the clustering of the metabolic syndrome (MetS) components (obese body mass index [BMI; ≥30 kg/m(2) ], hypertriglyceridemia, low high-density lipids, hypertension, and diabetes mellitus) in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) in the Consortium of Rheumatology Researchers of North America (CORRONA) Registry. METHODS: We included CORRONA participants with a rheumatologist-confirmed clinical diagnosis of PsA or RA with complete data. We used a modified definition of MetS that did not include insulin resistance, waist circumference, or blood pressure measurements. Logistic regression models were adjusted for age, sex, and race. RESULTS: In the overall CORRONA population, the rates of diabetes mellitus and obesity were significantly higher in PsA compared with RA. In 294 PsA and 1,162 RA participants who had lipids measured, the overall prevalence of MetS in PsA versus RA was 27% versus 19%. The odds ratio (OR) of MetS in PsA versus RA was 1.44 (95% confidence interval [95% CI] 1.05-1.96, P = 0.02). The prevalence of hypertriglyceridemia was higher in PsA compared with RA (38% versus 28%; OR 1.51 [95% CI 1.15-1.98], P = 0.003). The prevalence of type 2 diabetes mellitus was also higher in PsA compared with RA (15% versus 11%; OR 1.56 [95% CI 1.07-2.28], P = 0.02) in the adjusted model. Similarly, higher rates of hypertriglyceridemia and diabetes mellitus were observed in the subgroup of PsA and RA patients with obese BMI. CONCLUSION: Compared with RA, PsA is associated with higher rates of obesity, diabetes mellitus, and hypertriglyceridemia.
OBJECTIVE: We compared the prevalence and the clustering of the metabolic syndrome (MetS) components (obese body mass index [BMI; ≥30 kg/m(2) ], hypertriglyceridemia, low high-density lipids, hypertension, and diabetes mellitus) in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) in the Consortium of Rheumatology Researchers of North America (CORRONA) Registry. METHODS: We included CORRONAparticipants with a rheumatologist-confirmed clinical diagnosis of PsA or RA with complete data. We used a modified definition of MetS that did not include insulin resistance, waist circumference, or blood pressure measurements. Logistic regression models were adjusted for age, sex, and race. RESULTS: In the overall CORRONA population, the rates of diabetes mellitus and obesity were significantly higher in PsA compared with RA. In 294 PsA and 1,162 RAparticipants who had lipids measured, the overall prevalence of MetS in PsA versus RA was 27% versus 19%. The odds ratio (OR) of MetS in PsA versus RA was 1.44 (95% confidence interval [95% CI] 1.05-1.96, P = 0.02). The prevalence of hypertriglyceridemia was higher in PsA compared with RA (38% versus 28%; OR 1.51 [95% CI 1.15-1.98], P = 0.003). The prevalence of type 2 diabetes mellitus was also higher in PsA compared with RA (15% versus 11%; OR 1.56 [95% CI 1.07-2.28], P = 0.02) in the adjusted model. Similarly, higher rates of hypertriglyceridemia and diabetes mellitus were observed in the subgroup of PsA and RApatients with obese BMI. CONCLUSION: Compared with RA, PsA is associated with higher rates of obesity, diabetes mellitus, and hypertriglyceridemia.
Authors: S A Karvounaris; P I Sidiropoulos; J A Papadakis; E K Spanakis; G K Bertsias; H D Kritikos; E S Ganotakis; D T Boumpas Journal: Ann Rheum Dis Date: 2006-06-22 Impact factor: 19.103
Authors: L-S Tam; B Tomlinson; T T-W Chu; M Li; Y-Y Leung; L-W Kwok; T K Li; T Yu; Y-E Zhu; K-C Wong; E W-L Kun; E K Li Journal: Rheumatology (Oxford) Date: 2008-04-09 Impact factor: 7.580
Authors: Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala Journal: J Rheumatol Date: 2006-09-01 Impact factor: 4.666
Authors: Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein Journal: Atherosclerosis Date: 2007-01-30 Impact factor: 5.162
Authors: P Gisondi; G Tessari; A Conti; S Piaserico; S Schianchi; A Peserico; A Giannetti; G Girolomoni Journal: Br J Dermatol Date: 2007-06-06 Impact factor: 9.302
Authors: Lai-Shan Tam; Qing Shang; Edmund K Li; Brian Tomlinson; Tanya T W Chu; Martin Li; Ying-Ying Leung; Lai-Wa Kwok; Kong-Chiu Wong; Tena K Li; Tracey Yu; Tracy Y Zhu; Emily W Kun; Gabriel W Yip; Cheuk-Man Yu Journal: Arthritis Rheum Date: 2008-09-15
Authors: Alanna C Bridgman; Abrar A Qureshi; Tricia Li; Fred K Tabung; Eunyoung Cho; Aaron M Drucker Journal: J Am Acad Dermatol Date: 2019-02-21 Impact factor: 11.527
Authors: Juan Carlos Torre-Alonso; Loreto Carmona; Mireia Moreno; Eva Galíndez; Jesús Babío; Pedro Zarco; Luis Linares; Eduardo Collantes-Estevez; Manuel Fernández Barrial; Juan Carlos Hermosa; Pablo Coto; Carmen Suárez; Raquel Almodóvar; Jesús Luelmo; Santos Castañeda; Jordi Gratacós Journal: Rheumatol Int Date: 2017-04-07 Impact factor: 2.631
Authors: Rebecca Haberman; Lourdes M Perez-Chada; Joseph F Merola; Jose Scher; Alexis Ogdie; Soumya M Reddy Journal: Curr Rheumatol Rep Date: 2018-10-26 Impact factor: 4.592